secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042421
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q2 net loss narrows to $1.5M; FDA clears Ph1/Part B of ReSPECT-LM
--------------------------------------------------------------------------------

- Q2 2023 net loss of $1.5M ($0.59/share) vs $5.3M ($3.56/share) in Q2 2022.
- Cash balance $10.9M at June 30, 2023, down from $18.1M at Dec 31, 2022; expects $1.9M CPRIT grant soon.
- FDA approval to advance ReSPECT-LM trial to Phase 1/Part B for leptomeningeal metastases.
- Total operating expenses fell 35% YoY to $3.3M due to lower R&D spend after initial cGMP work.
- New VP of Clinical Operations Pius Maliakal appointed; expanded Piramal Pharma supply collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023042421/0000950170-23-042421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017023042421/pstv-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer